Paloma Partners’s Denali Therapeutics DNLI Stock Holding History

Paloma Partners’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-13,280	Closed	-$476K	–	1771
2020 Q3	$476K	Buy	+13,280	New	+$400K	0.01%	1199

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paloma Partners's DNLI Position: Q4 2020 in Review

Paloma Partners sold out of Denali Therapeutics (DNLI) in Q4 2020, closing a stake of 13,280 shares — an estimated $476K sold.

Paloma Partners first reported a position in DNLI in Q3 2020 and held it in 1 quarter. The position peaked at $476K in Q3 2020. 204 funds tracked by Wall St. Rank hold DNLI as of Q4 2020.

Paloma Partners reported no remaining Denali Therapeutics position as of Q4 2020 after selling out during the quarter.
Paloma Partners sold 13,280 Denali Therapeutics shares in Q4 2020, an estimated $476K.
Paloma Partners first reported a position in Denali Therapeutics in Q3 2020 and held it in 1 quarter.
Paloma Partners's Denali Therapeutics position peaked at $476K in Q3 2020.
204 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.